Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial ...

BTIG analysts raised the price target for Liquidia Corporation (NASDAQ:LQDA) from $37 to $45 and kept a “Buy” rating. This ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation’s LQDA Yutrepia (treprostinil) ...

This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Liquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025 ...

MannKind's pipeline and technology outweigh competitive risks and support future upside. See why we recommend a buy rating on ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog ...

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...

YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a ...